Market overview
The global new approach methodologies nonclinical testing market is worth USD 2.2 bn in 2026 and is forecast to reach USD 7.4 bn by 2036, growing at a 13.0% CAGR. United States is the largest country market and In vitro cell-based and 3D models is the largest by technology segment.
| Scope | Fee-based testing services built on human-relevant methods that replace or reduce animal studies: cell-based assays, organoids, organ-on-chip, computational toxicology and omics screening for drug, chemical and cosmetic safety. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 1.9 bn |
| Value 2026 | USD 2.2 bn |
| Value 2036 | USD 7.4 bn |
| CAGR 2026-2036 | 13.0% |
| Volume 2026 | 42,471 studies |
| Volume 2036 | 118,269 studies |
| Average price 2026 | USD 51,000 per studie |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
New Approach Methodologies Nonclinical Testing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 2.2 bn |
| 2027 | USD 2.4 bn |
| 2028 | USD 2.8 bn |
| 2029 | USD 3.1 bn |
| 2030 | USD 3.5 bn |
| 2031 | USD 4.0 bn |
| 2032 | USD 4.5 bn |
| 2033 | USD 5.1 bn |
| 2034 | USD 5.8 bn |
| 2035 | USD 6.5 bn |
| 2036 | USD 7.4 bn |
New Approach Methodologies Nonclinical Testing market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| In vitro cell-based and 3D models | 36.0% | 28.7% | USD 780 mn | 10.5% |
| Organ-on-chip and microphysiological systems | 12.0% | 26.5% | USD 260 mn | 22.3% |
| In silico and computational toxicology | 22.0% | 22.8% | USD 477 mn | 13.4% |
| High-throughput and omics screening | 20.0% | 15.9% | USD 433 mn | 10.5% |
| Other methods | 10.0% | 6.1% | USD 217 mn | 7.5% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Toxicity and safety assessment | 46.0% | 43.3% | USD 996 mn | 12.3% |
| ADME and pharmacokinetics | 22.0% | 22.7% | USD 477 mn | 13.3% |
| Efficacy and disease models | 20.0% | 24.5% | USD 433 mn | 15.3% |
| Other | 12.0% | 9.4% | USD 260 mn | 10.3% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical and biotechnology | 55.0% | 55.9% | USD 1.2 bn | 13.2% |
| Contract research organisations | 25.0% | 27.7% | USD 542 mn | 14.2% |
| Chemical and cosmetics | 12.0% | 10.2% | USD 260 mn | 11.2% |
| Academic and regulatory | 8.0% | 6.2% | USD 173 mn | 10.2% |
By model system
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| In vitro cell models | 40.0% | 38.0% | USD 866 mn | 12.4% |
| Organs-on-chips | 16.0% | 21.0% | USD 347 mn | 16.1% |
| In silico models | 24.0% | 25.0% | USD 520 mn | 13.5% |
| Organoids and 3D models | 20.0% | 16.0% | USD 433 mn | 10.5% |
By phase of use
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Discovery stage | 42.0% | 40.0% | USD 910 mn | 12.4% |
| Preclinical safety | 36.0% | 36.0% | USD 780 mn | 13.0% |
| Regulatory submission support | 22.0% | 24.0% | USD 477 mn | 14.0% |
Top 25 countries for new approach methodologies nonclinical testing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 95.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 823 mn | 38.0% | USD 2.8 bn | 12.8% |
| 2 | Germany | USD 173 mn | 8.0% | USD 529 mn | 11.8% |
| 3 | United Kingdom | USD 173 mn | 8.0% | USD 581 mn | 12.9% |
| 4 | China | USD 152 mn | 7.0% | USD 721 mn | 16.9% |
| 5 | France | USD 108 mn | 5.0% | USD 331 mn | 11.8% |
| 6 | Switzerland | USD 108 mn | 5.0% | USD 331 mn | 11.8% |
| 7 | Japan | USD 108 mn | 5.0% | USD 331 mn | 11.8% |
| 8 | Netherlands | USD 65 mn | 3.0% | USD 221 mn | 13.0% |
| 9 | Canada | USD 65 mn | 3.0% | USD 221 mn | 13.0% |
| 10 | South Korea | USD 54 mn | 2.5% | USD 213 mn | 14.7% |
| 11 | Australia | USD 36 mn | 1.7% | USD 121 mn | 12.9% |
| 12 | Belgium | USD 30 mn | 1.4% | USD 101 mn | 12.8% |
| 13 | Denmark | USD 26 mn | 1.2% | USD 88 mn | 12.9% |
| 14 | Sweden | USD 23 mn | 1.1% | USD 76 mn | 12.9% |
| 15 | Ireland | USD 20 mn | 0.9% | USD 67 mn | 12.9% |
| 16 | Austria | USD 19 mn | 0.9% | USD 62 mn | 12.9% |
| 17 | Israel | USD 17 mn | 0.8% | USD 57 mn | 12.8% |
| 18 | Singapore | USD 14 mn | 0.6% | USD 46 mn | 12.8% |
| 19 | Spain | USD 11 mn | 0.5% | USD 38 mn | 12.8% |
| 20 | Italy | USD 11 mn | 0.5% | USD 36 mn | 13.0% |
| 21 | India | USD 9.8 mn | 0.5% | USD 32 mn | 12.8% |
| 22 | Taiwan | USD 8.4 mn | 0.4% | USD 28 mn | 12.7% |
| 23 | Norway | USD 6.7 mn | 0.3% | USD 23 mn | 13.0% |
| 24 | Poland | USD 5.6 mn | 0.3% | USD 19 mn | 13.0% |
| 25 | Turkey | USD 5.0 mn | 0.2% | USD 16 mn | 12.5% |
| Rest of world | USD 94 mn | 4.3% | USD 307 mn | 12.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Charles River Laboratories
- Labcorp
- Eurofins Scientific
- WuXi AppTec
Group 2: Regional and specialist players
- Evotec
- Certara
- Inotiv
- MatTek
- Ncardia
- Pharmaron
- XCellR8
- Axion BioSystems
Group 3: Emerging and niche players
- Emulate
- MIMETAS
- CN Bio
- InSphero
- Simulations Plus
- TissUse
- Hesperos
- AxoSim
- Vivodyne
- Curi Bio
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the new approach methodologies nonclinical testing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.0% is calculated from the resulting values.
The market is divided by technology, by application, by end user, by model system, by phase of use. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the new approach methodologies nonclinical testing market?
The global new approach methodologies nonclinical testing market is estimated at USD 1.9 bn in 2025 and USD 2.2 bn in 2026.
How fast will the new approach methodologies nonclinical testing market grow?
It is forecast to reach USD 7.4 bn by 2036, a compound annual growth rate of 13.0% from 2026, an increase of USD 5.2 bn.
Which country is the largest market for new approach methodologies nonclinical testing?
United States is the largest market by revenue at USD 823 mn in 2026, 38.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 16.9% a year from 2026 to 2036.
Which new approach methodologies nonclinical testing segment is largest?
In the by technology split, In vitro cell-based and 3D models is the largest segment with 36.0% of 2026 revenue.
Who are the leading new approach methodologies nonclinical testing companies?
Global leaders include Charles River Laboratories, Labcorp, Eurofins Scientific, WuXi AppTec.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Amniotic MembraneUSD 2.2 bn · 8.5% CAGR
- Point-of-Care Respiratory Diagnostic PanelsUSD 2.2 bn · 6.5% CAGR
- Medical CannulaUSD 2.3 bn · 5.3% CAGR
- Dental SterilizationUSD 2.0 bn · 6.0% CAGR
- Tangential Flow FiltrationUSD 2.5 bn · 9.0% CAGR
- Cardiovascular Drug DiscoveryUSD 2.6 bn · 7.5% CAGR
- Healthcare APIUSD 1.8 bn · 16.0% CAGR
- Chromatography ResinUSD 2.6 bn · 9.8% CAGR